Action Pharma A/S

Italy's mid-sized pharmaceutical company Chiesi Farmaceutici SPA is continuing to build its interests in rare disease therapies with the acquisition of Denmark's Zymenex AS , which is developin

Over the past five years, biopharma alliance volume has declined, and so has the size of the up-front payments that are part of the financial lifeblood of smaller companies. But in this decline, an od

Exhibit 1 Top Alliances In May 2012 *Potential Deal Value is the sum of up-front fees plus disclosed pre-commercialization money. Elsevier’s Strategic Transactions Exhibit 2 Top Mergers & Acquisiti

Medicare’s “bundling” policy, intended to reduce drug spending in the dialysis setting, has turned pricing pressure into a choke hold in kidney disease. The cost containment policies for intravenous d